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How the heart senses increased biomechanic 
stress and converts this "input signal" to 
generalized downstream cardiac hypertrophy 
signaling paradigms remains an enigmatic but 
intriguing question in modern cardiovascular 
biology. Only recently have signaling molecules 
that can couple biomechanical stress to common 
pathways of cardiac hypertrophy been uncovered. 
Yeast-2-hybrid screens have identified several 
binding partners of sarcomeric proteins. These 
concerted actions revealed that especially the 
sarcomere Z-disc harbors key components that 
affect the activity of several notable kinases and 
phosphatase, including mitogen-activated protein 
kinases, protein kinases A and C, and calcineurin. 
[1] Exemplary to this is the family of calsarcin 
proteins, which link the Z-disk protein α-actinin to 
calcineurin, a well-characterized Ca2+-responsive 
signaling molecule controlling activity of the 
transcription factor NFAT and both required and 
sufficient for cardiac hypertrophy after pleiotropic 
stimuli (►Fig. 1). [2] However, interruption of the 
calcium overload typical for heart failure may not 
stop disease progression, and, therefore, Ca2+-
independent signaling cascades might serve as 
useful targets to interfere with left ventricular (LV) 
remodeling on pressure overload or ischemia. [3] 
Likewise, the giant sarcomeric protein titin is the 
starting point of a signaling complex where the 
zinc-finger protein nbr1 targets the ubiquitin-
associated p62/SQSTM1 to sarcomeres. In turn, 
p62 interacts with MuRF2, a muscle-specific RING-
B-box E3 ligase and ligand of the transactivation 
domain of the serum response transcription 
factor. Nuclear translocation of MuRF2, provoked 
by mechanical inactivity, causes reduction of 
nuclear serum response transcription factor and 
repression of serum response transcription factor–
mediated transcription (►Fig. 1). [4] Finally, 
cardiac mechanosensing might not be limited to 
the Z-disc only but can also derive from the M- 
and I-band regions, as well as the costamere, 
intercalated disks, and caveolae-like 
microdomains. [1]  
The study by Li et al [5] published in this issue of 
Hypertension now adds an interesting new player 
to this emerging field in the form of 
myofibrillogenesis regulator-1 (MR-1). The authors 
identified MR-1 earlier as a binding partner of the 
M-band proteins myosin regulatory light chain, 
myomesin, and ß-enolase (►Fig. 1). In the current 
work, they describe the phenotype of transgenic 
mice overexpressing human MR-1 in the heart 
muscle. The study complements previous 
observations by the authors that MR-1 is 
upregulated in a rat model of pathological cardiac 
hypertrophy secondary to angiotensin II (Ang II) 
infusion or abdominal aortic banding. Conversely, 
small interfering RNA–mediated knockdown of 
MR-1 inhibited cardiomyocyte hypertrophy in 
culture. The current article not only elevates their 
observations to an in vivo context but also 
provides some molecular insight to the workings 
of MR-1 in cardiac pathogenesis. 
MR-1 transgenic mice display no obvious baseline 
phenotype, which stimulated the authors to 
analyze the effect of MR-1 overexpression on Ang 
II–induced cardiac hypertrophy. Here, a rather 
high dose was chosen that not only leads to 
hypertrophy and severely elevated blood pressure 
but also to rapid decline of systolic LV function in 
control mice. Both changes, cardiac hypertrophy 
as determined by heart weight/body weight and 
LV remodeling resulting in severe LV dysfunction, 
were aggravated in MR-1–overexpressing mice. 
This observation was associated with an 
exaggerated increase in classical hypertrophy 
marker gene expression, inflammation, and 
fibrosis. 
Mechanistically, the authors linked their 
observations to NF-κB signaling. MR-1 
overexpression robustly increased NF-κB activity 
after Ang II stimulation as evidenced by DNA 
binding, p65 phosphorylation, IκBα 
phosphorylation and IκBα kinase activity. Likewise, 
adenoviral overexpression of MR-1 increased NF-
κB activity after Ang II treatment of isolated 
cardiomyocytes. In association with the effect on 
hypertrophy, small interfering RNA- mediated MR-
1 knockdown abolished NF-κB activity on Ang II 
treatment. In vitro, NF-κB activity was required 
downstream of MR-1 to evoke cardiomyocyte 
hypertrophy as adenoviral transfer of a mutated, 
nondegradable IκBα isoform abolished 
cardiomyocyte hypertrophy. Finally, the 
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authors also found increased levels of NF-κB 
regulated, proinflammatory cytokines membrane 
cofactor protein-1, interleukin-6, and tumor 
necrosis factor-α in association with increased 
fibrosis and collagen deposition in MR-1–
overexpressing mice. 
In summary, the authors propose a hierarchy of 
signaling events that places MR-1 at the 
sarcomere M-band at an integral point between 
cardiomoycte angiotensin receptor activation and 
NF-κB activation, which, in turn, drives cardiac 
hypertrophy and LV remodeling (►Fig. 1). 
Although the study has some limitations 
concerning the definition of hypertrophy 
(echocardiographic diastolic wall sizes and 
myofiber cross-sectional areas are missing), Ang II 
doses used (0.6 mg/kg per day leading to a blood 
pressure elevation of ≈40 mm Hg), and details on 
the MR-1–overexpressing mouse model, the 
findings are novel and interesting given the link 
between cardiac mechanosensing and specific 
Ca2+-independent nuclear signaling pathways. 
NF-κB activity has been associated with Ang II–
induced hypertrophy and LV remodeling in 
several previous publications. In vivo, heart-
restricted expression of a single copy of IκBαδN, a 
NF-κB superrepressor generating phenotypes 
similar to IκBα kinase knockouts when expressed 
globally, attenuates cardiac hypertrophy after Ang 
II and isoproterenol stimulation. [6] Upstream of 
NF-κB, Ang II was found to be a weak activator of 
DNA binding in adult rat cardiomyocytes; 
however, interleukin-6 cytokines released from 
cardiac fibroblasts on Ang II stimulation were 
found to be strong stimuli. [6] Furthermore, 
reactive oxygen species and the apoptosis signal-
regulating kinase 1 have been implicated in G 
protein–coupled receptor-induced cardiac 
hypertrophy mediated through NF-κB. [7] 
Downstream, NF-κB activity regulates mRNA and 
protein levels of the gp130 receptor known to be 
important for cardiomyocyte survival signaling 
and hypertrophy probably through an indirect 
mechanism. [6] In addition, iex-1 was identified as 
an biomechanical strain-induced, NF-κB 
dependent, antihypertrophic protein expressed in 
cardiomyocytes. [8] Also, using a model of 
mechanical strain applied on isolated 
cardiomyocytes, Liang et al [9] identified the p38 
mitogen-activated protein kinase/NF-κB axis to be 
required for B-type natriuretic peptide gene 
transcription. 
Therapeutically, peroxidase proliferator-activated 
receptor-γ activators have been found to inhibit 
cardiomyocyte hypertrophy via suppression of 
mechanically induced NF-κB activation. [10] NF-κB 
inhibition has been found to improve LV 
remodeling on experimental infarct via 
downregulation of metalloproteinase-9 activity 
known to be controlled transcriptionally by NF-κB. 
[11] In summary, the AngII/MR-1/NF-κB axis now 
adds a new player to the sarcomere-linked 
signaling cascades controlling LV remodeling on 
stress. Data are now needed that demonstrate 
inhibition of these factors to not only affect cardiac 
hypertrophy but also to preserve LV function in 
the presence of chronic pressure overload or 
ischemia. This would confirm MR-1 and NF-κB to 
be part of the maladaptive cardiac hypertrophy 
signaling complex. Data from genetically 
engineered mice with deletion of MR-1 are eagerly 
awaited to confirm the findings presented in the 
current article. 
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►Fig.1. Hypothetical signaling cascade linking Ang II signaling, cardiac mechanosensing at the 
sarcomere, and specific transcription factors in LV remodeling. 
 
